MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
LENSAR Accounts Receivables 2011-2026 | LNSR
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables LENSAR
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.08 M | 4 M | 6.04 M | 4.64 M | 2.01 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.08 M | 2.01 M | 4.56 M |
Quarterly Accounts Receivables LENSAR
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 M | 4.99 M | 6.88 M | 6.08 M | 4.37 M | 5.89 M | - | 4 M | 3.85 M | 3.22 M | 4.66 M | 6.04 M | 3.56 M | 2.76 M | 3.58 M | 4.64 M | 2.8 M | 2.7 M | 2.1 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 3.38 M | 3.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.88 M | 2.01 M | 3.87 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Medtronic PLC
MDT
|
6.52 B | $ 87.12 | 0.62 % | $ 112 B |  USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.13 | 6.22 % | $ 1.29 M | USA |
 |
Orthofix Medical
OFIX
|
136 M | $ 11.97 | 2.13 % | $ 474 M |  Curacao |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.3 | -0.4 % | $ 168 M | USA |
 |
IRadimed Corporation
IRMD
|
13.7 M | $ 102.82 | 1.83 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Insulet Corporation
PODD
|
161 M | $ 225.87 | 0.16 % | $ 15.9 B | USA |
 |
AxoGen
AXGN
|
26.2 M | $ 33.16 | 1.69 % | $ 1.53 B | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 36.85 | 0.72 % | $ 1.14 B | USA |
 |
AVITA Medical
RCEL
|
9.09 M | $ 4.04 | 5.21 % | $ 113 M |  Australia |
 |
NanoVibronix
NAOV
|
98 K | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.7 | 0.2 % | $ 209 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.65 | -7.27 % | $ 35.4 M | USA |
 |
Aethlon Medical
AEMD
|
128 K | $ 2.25 | 3.94 % | $ 3.51 M | USA |
 |
InspireMD
NSPR
|
2.17 M | $ 1.79 | 1.13 % | $ 115 M |  Israel |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Sintx Technologies
SINT
|
178 K | $ 2.62 | 1.95 % | $ 7.27 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 11.61 | 1.13 % | $ 1.57 B | USA |
 |
Myomo
MYO
|
4.1 M | $ 0.72 | 3.24 % | $ 30.1 M | USA |
 |
Penumbra
PEN
|
190 M | $ 335.79 | 0.46 % | $ 13.1 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
112 K | $ 2.4 | - | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.69 | -5.63 % | $ 138 M |  France |
 |
Sensus Healthcare
SRTS
|
6.04 M | $ 3.96 | - | $ 64.7 M | USA |
 |
Quanterix Corporation
QTRX
|
30 M | $ 3.95 | 3.4 % | $ 168 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 16.04 | 0.82 % | $ 376 M | USA |
 |
Outset Medical
OM
|
28.3 M | $ 3.56 | 0.85 % | $ 54.2 K | USA |